Please ensure Javascript is enabled for purposes of website accessibility

Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment

By Mark Prvulovic - Jan 28, 2020 at 8:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both primary as well as multiple secondary endpoints were met in the trial.

Akcea Therapeutics (AKCA) and Ionis Pharmaceuticals (IONS 2.81%) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- LRx, a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and hypertriglyceridemia (elevated triglyceride levels) showed significant improvements in their blood work.

A total of 105 patients with one of those three conditions were administered AKCEA-ANGPTL3- LRX via subcutaneous injection for six months. The results found there was a significant reduction in the levels of fasting triglycerides in comparison to the placebo, as well as other lipid indicators such as very-low-density lipoprotein (VLDL-C). The drug was well tolerated among patients, with the most common side effect being a mild reaction where the injection was administered. The full details of this study will be presented at a later medical conference, although it wasn't mentioned which one.

A person holding one of many test tubes, with this one being a test for triglyceride levels.

Image source: Getty Images.

AKCEA-ANGPTL3- LRX was first discovered and developed by Ionis, before being spun off and further developed by Akcea. Ionis still owns a 75% stake in the company, with Novartis choosing not to exercise an option to own a portion of the rights to the drug back in December. 

Further details

Back in October, Akcea announced a licensing agreement with Pfizer, with the former receiving $250 million upfront from the pharmaceutical giant, and half of that amount going to Ionis. The agreement goes on to state that Pfizer will take over developing the drug candidate now that this phase 2 study is finished.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$38.06 (2.81%) $1.04
Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.
AKCA
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12
Novartis AG Stock Quote
Novartis AG
NVS
$84.36 (-0.20%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.